Avalo Therapeutics Inc. has announced new compensation terms for its recently appointed executives. Taylor Boyd, the new Chief Business Officer, has been granted 275,000 non-qualified stock options, while Ashley Ivanowicz, Senior Vice President of Human Resources, has received 100,000 non-qualified stock options. The options vest over four years, with 25% vesting after the first year and the remainder vesting in equal monthly installments over the following three years. The exercise price for the options will be set at the closing price of Avalo's common stock on October 1, 2025.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avalo Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001534120-25-000009), on October 01, 2025, and is solely responsible for the information contained therein.